Appia Bio is a biotechnology startup dedicated to the discovery and development of allogeneic cell therapies with a scalability that increases access for cancer patients.
Market:Cell therapy has brought dramatic improvements in efficacy and durable remission rates in certain hematological cancers, but it has reached a limited number of patients. In the autologous form, cell therapy’s individualized therapeutic approach is logistically complex, takes time to produce, and is associated with extremely high costs. Through breakthrough engineering technologies, we aim to make cell therapy readily available for patients by generating allogeneic and off-the-shelf products.
Technology:Our novel, proprietary platform can programmably generate a broad array of NKT and T cell types from hematopoietic stem cells.
- Allogeneic, off-the-shelf for broader access for patients
- Programmable-determination of cell lineage
- Scalable manufacturing
Back to Top